A detailed history of Met Life Investment Management, LLC transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 16,349 shares of JANX stock, worth $889,222. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,349
Previous 9,061 80.43%
Holding current value
$889,222
Previous $341,000 100.59%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$35.12 - $64.78 $255,954 - $472,116
7,288 Added 80.43%
16,349 $684,000
Q1 2024

May 14, 2024

BUY
$7.93 - $49.75 $71,853 - $450,784
9,061 New
9,061 $341,000
Q2 2023

Apr 29, 2024

BUY
$11.08 - $15.92 $117,603 - $168,974
10,614 New
10,614 $125,000
Q1 2023

May 09, 2024

BUY
$11.25 - $22.21 $119,407 - $235,736
10,614 New
10,614 $128 Million
Q1 2022

May 10, 2024

BUY
$13.24 - $20.24 $140,529 - $214,827
10,614 New
10,614 $152,000
Q1 2022

Mar 22, 2023

BUY
$13.24 - $20.24 $70,330 - $107,514
5,312 Added 100.19%
10,614 $152,000
Q1 2022

May 12, 2022

BUY
$13.24 - $20.24 $70,330 - $107,514
5,312 Added 100.19%
10,614 $152,000
Q4 2021

Jun 21, 2023

SELL
$15.44 - $27.32 $82,017 - $145,123
-5,312 Reduced 50.05%
5,302 $104,000
Q3 2021

May 17, 2024

SELL
$20.7 - $34.69 $77,811 - $130,399
-3,759 Reduced 41.49%
5,302 $114,000
Q3 2021

Jun 21, 2023

SELL
$20.7 - $34.69 $109,958 - $184,273
-5,312 Reduced 50.05%
5,302 $114,000
Q3 2021

Mar 22, 2023

SELL
$20.7 - $34.69 $109,958 - $184,273
-5,312 Reduced 50.05%
5,302 $114,000
Q3 2021

Nov 15, 2021

BUY
$20.7 - $34.69 $109,751 - $183,926
5,302 New
5,302 $115,000

Others Institutions Holding JANX

About Janux Therapeutics, Inc.


  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $2.27B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.